Health Canada says AstraZeneca shot is safe as U.S. questions vaccine's clinical trial data

Health Canada said today Canadians should not be concernedabout the safety of the AstraZeneca vaccine even as a U.S. regulatory body raisesconcerns about the company's clinical trial results.

Marc Berthiaume, the director of the bureau of medical science at Health Canada, said the issues flagged Monday by a U.S. federal health agency relate to the product's published efficacy rate, not to whetherit'ssafe to use.

Berthiaume said Health Canada's decision to authorize the product was not based on any of the clinical trial information U.S. authorities are now probing. He saidCanada based its approval largely on data that emerged from AstraZenecatrials in the United Kingdom and Brazil, and onstudies published in countries where the shot has been in use for some time.

"I think it would be alarmist to suggest that the results of additional clinical testing could lead to a change in the approval status of AstraZeneca here in Canada," Berthiaume said.

"The additional information that was collected in the U.S. will be sent to Health Canada in the coming weeks. If there's a need to readjust, then we'll do that with Canadians later."

Millions of people have received the AstraZeneca shot worldwide, includingmore than 17 million in Britain and the European Union almost all without serious side effects.

Health Canada 'concerned' about vaccine hesitancy

Dr. Supriya Sharma, Health Canada's chief medical adviser, said U.S. questions about the efficacy rate change nothing for Canadians at this point. She conceded thebarrage of headlines about the AstraZeneca shot are "something of a concern to us" because theycouldmake some Canadians reluctantto take vaccines.

"We've said this many times before that even the most effective vaccine only works if people trust it and agree to receive it," she said.

"It's like any other reputation. Once there's some doubt that creeps into that reputation, it's that much more difficult to gain that back. The press and the concerns around the AstraZeneca vaccine don't help."

WATCH: Health Canada says federal recommendations on AstraZeneca vaccine are not changing

Sharma says federal recommendations on AstraZeneca vaccine are not changing

3 years ago

Duration 1:40

Dr. Supriya Sharma, Health Canadas chief medical adviser, says federal recommendations on the use of AstraZeneca's COVID-19 vaccine are not changing at this point in time.

In a statement released last night, the National Institute of Allergy and Infectious Diseases (NIAID) in the U.S.said the Data and Safety Monitoring Board (DSMB), which keeps an eye on clinical trials, found "outdated information" may have been reported by the company when it released some informationyesterday.

The agency said the British-Swedish pharmaceutical giant may have released information that gives an "incomplete view of the efficacy data."

"We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible,"the agency said without stating what sort of data may have been includedimproperly.

The statement came only hours after AstraZeneca released the results of its U.S.-based phase three clinical trials, which began last August and wrapped up earlier this month. Phase three is the point in a clinical trialwhena vaccine maker gathers more information about safety and effectiveness and studies the effect of different doses on various groups.

The company said its COVID-19 vaccinehad a 79 per cent efficacy rate forpreventing symptomatic COVID-19 and has 100 per cent efficacyin stopping severe disease and hospitalization. Investigators said the vaccine was effective for adults of all ages, including older people something which previous studies in other countries had failed to establish.

The product has not yet been authorized for use in the U.S.

Speaking to ABC's Good Morning America on Tuesday, Dr. Anthony Fauci, U.S. President Joe Biden's chief medical adviser and the head of the NIAID, said the monitoring board was surprised by thethe better-than-expectedefficacy resultspublished by AstraZeneca.

"They got concerned and wrote a rather harsh note to them and with a copy to me, saying that in fact they felt that the data that was in the press release were somewhat outdated and might in fact bemisleading a bit, and wanted them to straighten it out," Fauci said.

The board memberspegged the vaccine's efficacy at between 69 per cent 74 per cent up to 10 points lower than what AstraZeneca itself reported and said the company's decision to issue a press release with better results served to erodepublic trust.

"We told the company they better get back with the DSMB and make surethe correct data get put into a press release."

In response to the blowback,AstraZeneca said the efficacy numbers it released yesterday were current as of February 17 a month before theclinical trial was actually completed. In a statement, thecompany said itwould "immediately engage with the independent data safety monitoring board" and provide the U.S. regulatorwith "the results of the primary analysis within 48 hours."

This is just the latest public communications issue the company has faced over the last three months.

Earlier this year, a number of European countries halted vaccinations in response to questions about the product's efficacy in people over the age of 65, only to restart them after new evidence emerged.

After Health Canada approved the shot for all adults, the National Advisory Committee on Immunization (NACI) recommended the product be used onlyon people under the age of 65, citing a dearth of clinical trial data on the vaccine's effectiveness in older people.

NACI changed course last week after reviewing three "real-world studies," saying the two-dose viral vector vaccine can and should be used on seniors.

The European Medicines Agency has also had to assure European Union member countries that the product is safe to use after reports of post-vaccine blood clots in a very small number of patients.

The agency concluded that the benefits of protecting against COVID-19 which itself results in clotting problems outweigh the risks.

The Public Health Agency of Canada has said it's "possible" the vaccine may be associated with "very rare but serious cases of blood clots associated with thrombocytopenia" a condition associated with very low levels of blood platelets.Health Canada has maintained that the benefits of the AstraZeneca COVID-19 vaccine continue to outweigh the risks.